Dr. David M. Dewolfe, MD

Dr. Dewolfe practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. Dewolfe's NPI, 1154614386, was assigned on May 20, 2011. Dr. Dewolfe holds New York license 288665.

Dr. Dewolfe's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. Dewolfe's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. Dr. Dewolfe is also affiliated with Upstate University Hospital. The medical group on file is Strong Renal Group. Dmand AI also links Dr. Dewolfe to 2 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dewolfe practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Dewolfe's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Dewolfe's licenses on file in 3 states: New York, Massachusetts and Rhode Island.

CMS data shows 876 Medicare services from Dr. Dewolfe across 5 procedure codes in 2024, for 135 Medicare patients. Medicare paid $72,444 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 135 Medicare patients who saw Dr. Dewolfe in 2024. The largest group is under 65, with 79 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 47% are also on Medicaid. Their average risk score is 5.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dewolfe's median patient age at 61, with 40% women.

In 2024, Dr. Dewolfe wrote 1,676 Medicare Part D claims for 108 patients. 88% of them were for generic drugs. CMS names the drug for 1,483 of them, across 34 drugs with 11 or more claims each, at $111,523 in total drug cost. In 2023, CMS named 1,393 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Dewolfe for performance year 2024, reported as part of a group. Dr. Dewolfe accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Dewolfe, published from 2017 to 2025. 2019 was the busiest year, with 2. The most frequent topics are Kidney Transplantation, BK Virus and CD4-Positive T-Lymphocytes. Dr. Dewolfe's most frequent co-authors are Martha Pavlakis, MD, Francesca Cardarelli, MD and Anil Kumar Chandraker, MBCHB.

CMS Open Payments shows 2 general payments to Dr. Dewolfe from 1 drug or device company from 2018 to 2023. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $108.